The 2-[(18)F]fluoropropionic (2-[(18)F]FPA) acid is used as a prosthetic group for radiolabeling proteins and peptides for targeted imaging using positron emission tomography (PET). Radiolabeling of compounds with more than one acylable functional group can lead to complex mixtures of products; however, peptides can be labeled regioselectively on the solid phase. We investigated the use of a solid-phase approach for the preparation of 2-[(18)F]fluoropropionyl peptides. [(18)F]FPA was prepared and conjugated to the peptides attached to the solid phase support. The (18)F-labeled peptides were obtained in 175 min with decay corrected yields of 10% (related to [(18)F]fluoride) and with a purity of 76-99% prior HPLC purification. The suitability of various coupling reagents and solid supports were tested for radiolabeling of several peptides of various lengths.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/bc0600564 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Single Amino Acid Replacement in G-7039 Leads to a 70-fold Increase in Binding toward GHS-R1a.
ChemMedChem
October 2019
Department of Chemistry, University of Western Ontario, 1151 Richmond Street, London, ON, N6A 5B7, Canada.
The growth hormone secretagogue receptor type 1a (GHS-R1a) is a class A rhodopsin-like G protein coupled receptor (GPCR) that is expressed in a variety of human tissues and is differentially expressed in benign and malignant prostate cancer. Previously, the peptidomimetic [1-Nal ,Lys (4-fluorobenzoyl)]G-7039 was designed as a molecular imaging tool for positron emission tomography (PET). However, this candidate was a poor binder (IC =69 nm), required a lengthy four-step radiosynthesis, and had a cLogP above 8.
View Article and Find Full Text PDFF-FPPRGD PET/CT in patients with metastatic renal cell cancer.
Eur J Nucl Med Mol Imaging
July 2019
Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, 300 Pasteur Drive, Stanford, CA, 94305-5281, USA.
Purpose: The usefulness of positron emission tomography/computed tomography (PET/CT) using (F)-2-fluoropropionyl-labeled PEGylated dimeric arginine-glycine-aspartic acid peptide [PEG3-E{c(RGDyk)}2] (F-FPPRGD) in patients with metastatic renal cell cancer (mRCC) has not been evaluated; therefore, we were prompted to conduct this pilot study.
Methods: Seven patients with mRCC were enrolled in this prospective study. F-FPPRGD and 2-deoxy-2-(F)fluoro-D-glucose (F-FDG) PET/CT images were evaluated in a per-lesion analysis.
Biodistribution of the ¹⁸F-FPPRGD₂ PET radiopharmaceutical in cancer patients: an atlas of SUV measurements.
Eur J Nucl Med Mol Imaging
November 2015
Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, CA 300 Pasteur Drive, C21, Stanford, CA, 94305-5281, USA.
Purpose: The aim of this study was to investigate the biodistribution of 2-fluoropropionyl-labeled PEGylated dimeric arginine-glycine-aspartic acid (RGD) peptide (PEG3-E[c{RGDyk}]2) ((18)F-FPPRGD2) in cancer patients and to compare its uptake in malignant lesions with (18)F-FDG uptake.
Methods: A total of 35 patients (11 men, 24 women, mean age 52.1 ± 10.
Glioblastoma Multiforme Recurrence: An Exploratory Study of (18)F FPPRGD2 PET/CT.
Radiology
November 2015
From the Division of Nuclear Medicine and Molecular Imaging (A.I., C.M., E.M.), Department of Radiology, Neuroradiology Section (G.Z., N.F.), Division of Neurosurgery (G.H., G.L.), and Division of Neuro Oncology (S.N., L.R.), Stanford University Medical Center, 300 Pasteur Dr, Room H-2200, Stanford, CA 94305; and Departments of Radiology, Bioengineering, Materials Science, and Engineering, Stanford University School of Medicine, Stanford, Calif (S.S.G.).
Purpose: To prospectively evaluate fluorine 18 ((18)F) 2-fluoropropionyl-labeled PEGylated dimeric arginine-glycine-aspartic acid (RGD) peptide (PEG3-E[c{RGDyk}]2) (FPPRGD2) positron emission tomography (PET) in patients with glioblastoma multiforme (GBM).
Materials And Methods: The institutional review board approved this HIPAA-compliant protocol. Written informed consent was obtained from each patient.
(18)F-FPPRGD2 PET/CT: pilot phase evaluation of breast cancer patients.
Radiology
November 2014
From the Division of Nuclear Medicine and Molecular Imaging (A.I., C.M., E.M.), Molecular Imaging Program at Stanford (B.S., F.T.C.), Division of Medical Oncology (M.L.T.), and Departments of Radiology, Bioengineering, and Materials Science and Engineering (S.S.G.), Stanford University Medical Center, 300 Pasteur Dr, Room H-0101, Stanford, CA 94305.
Purpose: To present data from the first prospective pilot phase trial of breast cancer participants imaged with fluorine 18 ((18)F)-2-fluoropropionyl-labeled PEGylated dimeric arginine-glycine-aspartic acid ( RGD arginine-glycine-aspartic acid ) peptide (PEG3-E[c{ RGD arginine-glycine-aspartic acid yk}]2) ( FPPRGD2 2-fluoropropionyl labeled PEGylated dimeric RGD peptide (PEG3-E[c{RGDyk}]2) ), a radiopharmaceutical agent used in positron emission tomographic (PET) imaging.
Materials And Methods: The local institutional review board approved the HIPAA-compliant protocol. Written informed consent was obtained from each patient.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!